While decreased neuronal glucose metabolism and associated altered bioenergetics are recognized as a common feature in AD, its extent and relationships with the “core” pathological processes of AD, i.e., amyloid pathology and tau-related neurodegeneration, necessitate further investigation [1, 34–36]. This evidence concerns the gene MAPT and Alzheimer disease.